Vanguard Group Inc. boosted its position in UiPath Inc. (NYSE:PATH - Free Report) by 5.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,217,936 shares of the healthcare company's stock after acquiring an additional 2,133,078 shares during the quarter. Vanguard Group Inc. owned 7.07% of UiPath worth $911,741,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also added to or reduced their stakes in PATH. Norges Bank bought a new position in shares of UiPath during the fourth quarter valued at about $165,749,000. Artisan Partners Limited Partnership bought a new position in shares of UiPath during the fourth quarter valued at about $48,267,000. Vestmark Advisory Solutions Inc. bought a new position in shares of UiPath during the fourth quarter valued at about $15,543,000. First Trust Advisors LP grew its stake in shares of UiPath by 122.6% during the fourth quarter. First Trust Advisors LP now owns 1,132,984 shares of the healthcare company's stock valued at $28,143,000 after buying an additional 624,003 shares during the last quarter. Finally, Trexquant Investment LP grew its stake in shares of UiPath by 303.7% during the fourth quarter. Trexquant Investment LP now owns 741,506 shares of the healthcare company's stock valued at $18,419,000 after buying an additional 557,828 shares during the last quarter. Institutional investors own 62.50% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on the company. Bank of America reaffirmed a "neutral" rating and set a $16.00 price objective (down from $30.00) on shares of UiPath in a research note on Thursday, May 30th. Scotiabank cut their target price on UiPath from $30.00 to $25.00 and set a "sector perform" rating on the stock in a research note on Wednesday, May 29th. Mizuho cut their target price on UiPath from $25.00 to $14.00 and set a "neutral" rating on the stock in a research note on Thursday, May 30th. DA Davidson cut their target price on UiPath from $24.00 to $13.00 and set a "neutral" rating on the stock in a research note on Thursday, May 30th. Finally, BMO Capital Markets cut their target price on UiPath from $28.00 to $14.00 and set a "market perform" rating on the stock in a research note on Monday, June 3rd. Sixteen analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $18.06.
Read Our Latest Report on UiPath
UiPath Price Performance
PATH traded down $0.38 on Wednesday, hitting $11.93. The company had a trading volume of 9,710,320 shares, compared to its average volume of 9,908,147. The stock has a fifty day simple moving average of $13.62 and a 200-day simple moving average of $19.23. UiPath Inc. has a 52-week low of $11.07 and a 52-week high of $27.87. The firm has a market capitalization of $6.83 billion, a P/E ratio of -74.56 and a beta of 0.86.
UiPath (NYSE:PATH - Get Free Report) last released its earnings results on Wednesday, May 29th. The healthcare company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03). UiPath had a negative net margin of 6.41% and a negative return on equity of 2.97%. The firm had revenue of $335.11 million during the quarter, compared to analyst estimates of $332.84 million. Equities research analysts expect that UiPath Inc. will post -0.22 earnings per share for the current fiscal year.
Insider Activity
In other news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $19.79, for a total transaction of $791,600.00. Following the completion of the transaction, the chief financial officer now directly owns 946,848 shares in the company, valued at $18,738,121.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 22.37% of the company's stock.
UiPath Profile
(
Free Report)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Featured Articles
![Institutional Ownership by Quarter for UiPath (NYSE:PATH)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&Symbol=PATH)
Before you consider UiPath, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.
While UiPath currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.